Press

The leap from raising seed funding to landing a Series A was difficult for RxRevu CEO Carm Huntress, as it typically is for many in the digital health space.

In the first five months of 2020, RxRevu hit a number of key milestones in the success of their SwiftRx Direct solution.

This week, 35+ companies stepped up efforts to prevent the spread of COVID-19 here in Colorado and beyond.

RxRevu achieved unprecedented growth in 2019, advancing its position as the leader in Prescription Decision Support. In only eight months, use of RxRevu’s integrated prescription cost transparency solution, SwiftRx® Direct™, grew from less than ten health systems, to more than 320 health systems across the country.

Surprise bills happen when patients are billed at highly inflated prices from out-of-network providers they didn’t select in advance.

RxRevu has reached an agreement with Cerner to integrate its pharmacy and patient prescription pricing solution into the EHR to help providers choose the most cost-effective medication for patients.

RxRevu, the nation’s only independent provider of integrated prescription cost transparency solutions, announced today it has entered into an agreement with Epic, the leading provider of EHR software.

What started as a book of pharmaceuticals organized by efficacy and cost has been built into a Denver startup that has recently raised $15.9 million through its partnership with UCHealth.

At the 2019 HLTH Conference, Carm Huntress was invited to the stage to discuss drug price transparency and the hopes for the future of the industry.

The funding will fuel RxRevu’s continued growth as the only independent provider of EHR-integrated tools that assist clinicians in prescribing the right medication at the lowest patient cost possible.

UCHealth today announces the launch of the only independent real-time benefit and cost transparency solution in the country across the health care system’s hospitals and clinics.

Building alternative revenue sources will play a bigger role in healthcare providers' strategies, according to a new study.